Sarilumab - Biologic Drug Details

Summary for sarilumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for sarilumab

Recent Clinical Trials for sarilumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
M.D. Anderson Cancer Center	Phase 1
John Harris	Phase 2/Phase 3
NYU Langone Health	Phase 2

See all sarilumab clinical trials

Pharmacology for sarilumab

Mechanism of Action	Interleukin 6 Receptor Antagonists
Established Pharmacologic Class	Interleukin-6 Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for sarilumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for sarilumab Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for sarilumab Derived from Patent Text Search

No patents found based on company disclosures

Sarilumab Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory of Sarilumab

Introduction

Sarilumab, a humanized monoclonal antibody, has emerged as a significant player in the biopharmaceutical market for its role in treating moderate to severe rheumatoid arthritis (RA) and other autoimmune diseases. This article delves into the market dynamics and financial trajectory of sarilumab, highlighting its growth, market segmentation, competitive landscape, and future prospects.

Market Size and Growth

The global sarilumab market size was valued at USD 345.10 million in 2024 and is projected to reach USD 613.11 million by 2032, with a compound annual growth rate (CAGR) of 7.45% from 2025 to 2032[1]. This growth is driven by the increasing adoption of biologic therapies for autoimmune diseases and the expanding use of sarilumab for COVID-19 treatment.

Market Segmentation

The sarilumab market is segmented by dosage (Injection and Solution), route of administration (Subcutaneous and Parenteral), type (Antirheumatic, Interleukin-6 Receptor Antagonist, and Monoclonal Antibody), application (Rheumatoid Arthritis, Community-acquired Pneumonia, and Others), demographic (Adult and Geriatric), end-users (Clinic, Hospital, and Others), and distribution channels (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)[1].

Competitive Landscape

The market is dominated by major players such as Regeneron Pharmaceuticals Inc. and Sanofi. These companies have a long-standing partnership to develop and commercialize innovative medicines, including sarilumab. Sanofi and Regeneron have expanded the approval of sarilumab to include the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in children, further driving its market penetration[1][4].

Regional Market Analysis

North America holds a dominant position in the sarilumab market, driven by the presence of leading pharmaceutical companies and advanced healthcare infrastructure. The region's strong market presence of established brands and healthcare institutions supports continued growth in the sarilumab market[1]. Asia-Pacific is anticipated to experience significant growth during the forecast period, driven by increasing focus on advancing therapies for various diseases and government initiatives supporting healthcare infrastructure and innovation[1].

Financial Trajectory

Sanofi, one of the key players in the development and distribution of sarilumab, reported a 10.2% sales growth in Q2 2024, with Dupixent sales up 29.2% to €3,303 million[2]. The company's robust performance is attributed to strong sales of Dupixent and new launches like ALTUVIIIO, Nexviazyme, Rezurock, and Sarclisa. Despite the negative impact of COVID-19 on vaccines sales, Sanofi's overall business EPS(1) was €1.73, up 4.0% at CER[2].

Future Prospects

The sarilumab market is poised for continued growth and expansion due to ongoing clinical trials investigating its potential in other autoimmune diseases such as systemic juvenile idiopathic arthritis (sJIA) and giant cell arteritis. Additionally, the drug's effectiveness in reducing inflammation in severe COVID-19 cases has further boosted its demand[1]. However, challenges such as competition from other RA biologics, concerns over side effects, and high treatment costs may limit accessibility in low-resource regions[1].

Key Takeaways

1. Market Size and Growth: The global sarilumab market size is projected to reach USD 613.11 million by 2032, with a CAGR of 7.45% from 2025 to 2032[1].
2. Market Segmentation: The market is segmented by dosage, route of administration, type, application, demographic, end-users, and distribution channels[1].
3. Competitive Landscape: Regeneron Pharmaceuticals Inc. and Sanofi are major players in the market, with Sanofi and Regeneron jointly developing and marketing sarilumab[1][4].
4. Regional Market Analysis: North America dominates the market due to advanced healthcare infrastructure and strong market presence of established brands[1]. Asia-Pacific is expected to experience significant growth driven by government initiatives and increasing focus on advancing therapies[1].
5. Financial Trajectory: Sanofi reported a 10.2% sales growth in Q2 2024, with Dupixent sales up 29.2% to €3,303 million[2].
6. Future Prospects: Ongoing clinical trials and the drug's effectiveness in treating severe COVID-19 cases are expected to drive future growth, despite challenges related to competition and accessibility[1].

FAQs

1. What is the current market size of sarilumab? The global sarilumab market size was valued at USD 345.10 million in 2024[1].

2. What is the expected growth rate of the sarilumab market? The market is expected to grow at a CAGR of 7.45% from 2025 to 2032[1].

3. Who are the major players in the sarilumab market? Regeneron Pharmaceuticals Inc. and Sanofi are the major players in the market, with Sanofi and Regeneron jointly developing and marketing sarilumab[1][4].

4. Which region dominates the sarilumab market? North America dominates the market due to advanced healthcare infrastructure and strong market presence of established brands[1].

5. What are the future prospects for sarilumab? Ongoing clinical trials and the drug's effectiveness in treating severe COVID-19 cases are expected to drive future growth, despite challenges related to competition and accessibility[1].

References

1. Data Bridge Market Research. (n.d.). Global Sarilumab Market.
2. Sanofi. (2024, July 25). Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgraded.
3. Sanofi. (2024, April 25). Press Release Sanofi Q1: robust 7% sales growth driven by Dupixent and new launches.
4. Market Statsville Group. (n.d.). Sarilumab Market Size, Share and Trends Analysis by 2033.